SPRO Spero Therapeutics, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
03:09
Jun 05
Jun 05
Long SPRO on FDA approval and GSK milestones
Spero Therapeutics is a long because its oral carbapenem tebipenem is nearing a June 18 FDA ruling, with the author arguing approval is almost assured after a strong trial and GSK handling ex-US development and sales. Approval would unlock $76 million launch and $25 million later milestone payments plus royalties, while Spero's $56 million cash and potential commercial/sales milestones support a $5-$7 base-case value versus the current $3 price. The stated swing factors are FDA labeling restrictions, which will dictate commercial success, and the company's request for 120 million new shares, which the author flags as odd though possibly tied to strategic deals. Timeframe is the June 18 FDA catalyst, with no longer horizon specified.
HIGH
About SPRO Investor Commentary
Across the available history and selected sources, Buzzberg tracks SPRO (Spero Therapeutics, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/nbaphilly17.